Uroplasty (NASDAQ: UPI) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it contrast to its peers? We will compare Uroplasty to related companies based on the strength of its profitability, analyst recommendations, institutional ownership, dividends, valuation, earnings and risk.
Valuation & Earnings
This table compares Uroplasty and its peers top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Uroplasty Competitors||$1.67 billion||$207.58 million||97.47|
Institutional and Insider Ownership
54.4% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 10.3% of shares of all “Medical Devices & Implants” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Volatility and Risk
Uroplasty has a beta of -1.26, indicating that its stock price is 226% less volatile than the S&P 500. Comparatively, Uroplasty’s peers have a beta of 0.47, indicating that their average stock price is 53% less volatile than the S&P 500.
This table compares Uroplasty and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations and price targets for Uroplasty and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Medical Devices & Implants” companies have a potential upside of 39.08%. Given Uroplasty’s peers higher probable upside, analysts clearly believe Uroplasty has less favorable growth aspects than its peers.
Uroplasty peers beat Uroplasty on 7 of the 9 factors compared.
Cogentix Medical, Inc. (Cogentix Medical) is a medical device company. The Company is engaged in the design, development, manufacturing and marketing of products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, known as EndoSheath technology, providing users with endoscope turnover. The Company’s products include Urgent PC Neuromodulation System, Macroplastique Bulking Agent, Endoscopy Systems and EndoSheath Technology. The Company is also engaged in the commercialization of the Urgent PC Neuromodulation System, a device which delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). Its Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) due to intrinsic sphincter deficiency (ISD). The Company offers 5000 and 7000 series of endoscopes, which are video endoscopy systems.
Receive News & Ratings for Uroplasty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uroplasty and related companies with MarketBeat.com's FREE daily email newsletter.